Girth/Length Surgery and Grafts
Dermal-Fat Grafts, AlloDerm / Acellular Dermal Matrix
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Cosmetic surgery; ADM not indicated for penile girth by guideline bodies
Reference only. Not medical advice.
What can go wrong
Seroma, wound infection, skin necrosis and skin loss, graft resorption/loss, contour deformity and asymmetry, and erectile discomfort ('dragging' sensation or pain) are all documented; some patients require graft removal. Revision surgery and dissatisfaction are meaningful risks given the modest average gain.
This is something to take to a clinician. The Atlas can tell you what is known about girth/length surgery and grafts in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Surgical girth augmentation wraps or inserts graft material - autologous dermal-fat grafts or acellular dermal matrix (ADM, e.g., AlloDerm) - around or beneath the penile skin to add circumference. Reported girth gains are modest (one ADM series ~1.1 cm at 3 months) but complication rates in published series are high: seromas, infection, skin necrosis, contour deformity, and a 'dragging' erectile discomfort are common, with one 78-patient ADM series reporting an overall complication rate near 72% and graft removal in several patients for severe complications. Grafts depend on neovascularization to survive; failure means matrix loss and necrosis. The ISSM has cautioned against ADM for penile girth enhancement.
Modest girth, high complication series - and grafts that can necrose.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Dermal-fat grafts add the patient's own dermis and fat as a bulking layer; ADM is a processed, cell-free scaffold intended to be repopulated by host cells and vessels. Added circumference comes from the interposed graft volume, which must revascularize to survive. Because the graft is not native erectile tissue, outcomes hinge on healing, and failed vascularization produces necrosis and contour problems.
Grafts that must survive to work
The Achilles' heel of graft augmentation is neovascularization. If the overlying skin or the graft fails to establish blood supply, the result is matrix loss, internal necrosis, seroma, and skin breakdown - not girth. Even when it 'works,' patients frequently report a dragging discomfort during erection and contour irregularity, which is why published series carry such high complication burdens and why guideline bodies are wary.
Safety in detail
This is an elective surgical procedure with substantial published complication rates including necrosis and graft loss; it requires evaluation by a qualified reconstructive surgeon. It is not endorsed for cosmetic girth enhancement by guideline bodies.
What people get wrong
Often saidSurgical grafts are the definitive, safe way to add girth
ActuallyPublished series report high complication rates (up to ~72% in one ADM cohort), including necrosis and graft removal; guideline bodies caution against ADM for cosmetic girth.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Cash-pay cosmetic surgery captures high per-case fees; complications and revisions generate additional paid procedures in an uninsured, lightly regulated market.
Set against the alternatives
Graft girth surgery trades the temporary/unpredictable profile of injectables for a permanent-but-complication-heavy surgical result. It is more invasive than HA filler with higher complication series and no clear durability advantage over safer temporary options; it is not endorsed for cosmetic girth by guideline bodies.
At a glance
- Reported girth gain
- ~1.1 cm (ADM series, 3 mo)
- ADM series complication rate
- ~72% overall in one 78-patient series
- Graft survival depends on
- Neovascularization; failure = necrosis
- ISSM stance
- Cautions against ADM for girth enhancement
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Girth/Length Surgery and Grafts. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
ADM (AlloDerm) penile girth augmentation series, 78 patients2019
Girth +~1.1 cm at 3 months; overall complication rate ~72%; several grafts removed for severe complications
ISSM review: acellular dermal matrix not recommended for penile girth enhancementrecent
Concluded ADM should not be recommended for cosmetic penile girth enhancement
Reviews of penile augmentation surgery outcomes2024
Grafting techniques show modest gains against notable complication and revision rates